TransCode Therapeutics

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.

Company to host investor update call Thursday, April 7, at 4:30 p.m. ET Company to host investor update call Thursday, April 7, at 4:30 p.m. ET

TransCode Therapeutics Reports 2021 Results; Provides Business Update

BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an interview with Co-Founder, President and CEO, Michael Dudley, will air on The RedChip Money Report® on Bloomberg TV on March 26 at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®

BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine . The article was published on March 21, 2022.

TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of Disorders

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE" earlier today by TransCode Therapeutics, Inc. (Nasdaq: RNAZ), please note that in the headline, the date of the conference should be 2022, not 2020 as previously stated. The corrected release follows:

CORRECTION --TransCode Therapeutics

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference.

TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer. The Company plans to advance its lead therapeutic candidate, designed to treat metastatic disease, into its First in Human clinical trial in 2022.

TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned for mid-next year. The presentation will be webcast and an archived recording will be made available in the Investors' section of the TransCode Therapeutics website.

TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today reported recent business progress and third quarter 2021 financial results. “TransCode has made further progress across our corporate infrastructure and bourgeoning portfolio, advancing our mission to design RNA therapeutics that can effectively treat cancer. Reflecting the

TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results

Boston, Massachusetts--(Newsfile Corp. - November 9, 2021) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced that it will be attending and presenting at the Q4 Virtual Investor Summit. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned...

TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced that Zdravka Medarova, Ph.D., has been appointed as the company's Chief Technology Officer effective October 1, 2021. Dr. Medarova is a scientific co-founder of TransCode and has served as a member of TransCode's advisory board since its found

TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer

TransCode Therapeutics (RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study. The post RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today appeared first on InvestorPlace.

RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today

Senmiao Technology

BEST Inc - ADR

Matinas BioPharma Hlds

ReWalk Robotics

These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks to Watch That Exploded Today, What You Need to Know

The stock price of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) is trading at over 75% during intraday trading today. This is why it happened.

RNAZ Stock: Why It Substantially Increased Today

Shares of TransCode Therapeutics Inc (NASDAQ: RNAZ) climbed by 65% on Thursday morning as the oncology company said in its press release that the preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. CEO Michael Dudley's remarks The preclinical study confirmed that intravenous injection of TTX-MC138 accumulates it in metastatic lesions, thereby […] The post Here's why TransCode Therapeutics stock is up about 65% on Thursday appeared first on Invezz.

Here's why TransCode Therapeutics stock is up about 65% on Thursday

TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.  Related:   TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development.

Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. The article, entitled “Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metas

TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today reported recent business progress and second quarter 2021 financial results. “2021 has so far been foundational for TransCode, highlighted by our recent initial public offering and listing on Nasdaq. With resources from the IPO and additional support from the NIH,

TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results

TransCode Therapeutics Inc (NASDAQ: RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138. TTX-MC138 is TransCode's lead therapeutic candidate for the treatment of metastatic solid tumors.

TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a platform company solving the challenge of RNA delivery in oncology, today announced that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate for the treatment of metastatic solid tumors. The award totals $2.3 million expected over three years. “We are honored that the NIH recognizes and supports

TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced the closing of its initial public offering of 7,187,500 shares of its common stock at a public offering price of $4.00 per share. Gross proceeds from the offering totaled $28,750,000, before deducting underwriting discounts

TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Over-allotment Option

Conyers Park III Acquisition Corp

Agrico Acquisition Corp

Sentage Holdings

After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million. Preclinical RNA biotech Transcode Therapeutics priced at $4 to raise $25 million at a $54 million market cap.

U.S. IPO Weekly Recap: Micro Caps Lead A Quiet 2 IPO Week

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics IPO Pricing Release

News for TransCode Therapeutics Stock (RNAZ)